CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.

Saved in:
Bibliographic Details
Title: CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.
Authors: Postow MA; Memorial Sloan Kettering Cancer Center, New York, New York, USA postowm@mskcc.org., Zang PD; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA., Pal SK; City of Hope Comprehensive Cancer Center, Duarte, California, USA., Mauguen A; Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Farwell M; Division of Nuclear Medicine and Molecular Imaging, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA., Gordon M; HonorHealth, Scottsdale, Arizona, USA., Hays D; CARTI Cancer Center, Little Rock, Arkansas, USA., Wong JYC; Department of Radiation Oncology, City of Hope Beckman Research Institute and Medical Center, Duarte, California, USA., Chen D; University of Washington, Seattle, Washington, USA., Ulaner GA; Department of Molecular Imaging Departments of Radiology and Translational Genomics, Therapy Hoag Family Cancer Institute, Irvine Los Angeles, California, USA.; Department of Molecular Imaging Departments of Radiology and Translational Genomics, University of Southern California, Los Angeles, California, USA., Esposito G; MedStar Georgetown University Hospital, Washington, DC, USA., McConathy J; University of Alabama at Birmingham Health System Authority, Birmingham, Alabama, USA., Graham MM; Department of Radiology, University of Iowa, Iowa city, Iowa, USA., Shields AF; Karmanos Cancer Institute, Detroit, Michigan, USA., Van den Abbeele AD; Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Butler MO; Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada., Thomas JS; USC Norris Comprehensive Cancer Center, Los Angeles, California, USA., Twardowski P; Department of Urologic Oncology, Providence Saint John's Health Center, Santa Monica, California, USA., Narang J; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA., Singh AP; Oncology Cell Therapy and Therapeutic Area Unit, Waltham, Massachusetts, USA., Dey A; Oncology Cell Therapy and Therapeutic Area Unit, Waltham, Massachusetts, USA., Maresca KP; WRDM, Pfizer Inc, Tewksbury, Massachusetts, USA., Keliher E; Pfizer Inc, New York, New York, USA., Liu F; Clinical Pharmacology and Translational Sciences, Pfizer Oncology Division, La Jolla, California, USA., Potdevin G; AstraZeneca US, Wilmington, Delaware, USA., Schmidt G; AstraZeneca US, Wilmington, Delaware, USA., Le W; ImaginAb Inc, Inglewood, California, USA., Wilson I; ImaginAb Inc, Inglewood, California, USA., Mascioni A; ImaginAb Inc, Inglewood, California, USA., Jia F; ImaginAb Inc, Inglewood, California, USA., Korn R; Radiology, Imaging Endpoints, Scottsdale, Arizona, USA., Ferris MR; ImaginAb Inc, Inglewood, California, USA., Schmiedehausen K; ImaginAb Inc, Inglewood, California, USA., Pandit-Taskar N; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Margolin KA; Medical Oncology, City of Hope National Medical Center, duarte, California, USA.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Mar 27; Vol. 14 (3). Date of Electronic Publication: 2026 Mar 27.
Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase II
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2025-012208